Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Wirth

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Urologic Oncology|January 1, 2019
Penile cancer - Incidence, mortality, and survival in Saxony, GermanyOlaf Schoffer, Anne Neumann, Roland Stabenow, et al.
European Urology|June 6, 2013
The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literatureGeorgios Gakis, Stephen A Boorjian, Alberto Briganti, et al.
European Urology Oncology|November 17, 2021
Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical TrialTobias Hölscher, Michael Baumann, Jörg Kotzerke, et al.
European Urology|September 5, 2018
Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social MediaHendrik Borgmann, Matthew Cooperberg, Declan Murphy, et al.
European Urology|June 26, 2019
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019Marc-Oliver Grimm, Axel Bex, Maria De Santis, et al.
The Lancet. Oncology|July 31, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialFred Saad, Joan Carles, Silke Gillessen, et al.
Cancers|May 14, 2022
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)Tobias Hölscher, Michael Baumann, Jörg Kotzerke, et al.
International Journal of Cancer|September 12, 2019
Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostateAngelika Borkowetz, Michael Froehner, Martina Rauner, et al.
European Urology|March 18, 2014
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, et al.
European Urology|May 24, 2011
The contemporary concept of significant versus insignificant prostate cancerGuillaume Ploussard, Jonathan I Epstein, Rodolfo Montironi, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Urologic Oncology|January 1, 2019
Penile cancer - Incidence, mortality, and survival in Saxony, GermanyOlaf Schoffer, Anne Neumann, Roland Stabenow, et al.
European Urology|June 6, 2013
The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literatureGeorgios Gakis, Stephen A Boorjian, Alberto Briganti, et al.
European Urology Oncology|November 17, 2021
Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical TrialTobias Hölscher, Michael Baumann, Jörg Kotzerke, et al.
European Urology|September 5, 2018
Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social MediaHendrik Borgmann, Matthew Cooperberg, Declan Murphy, et al.
European Urology|June 26, 2019
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019Marc-Oliver Grimm, Axel Bex, Maria De Santis, et al.
The Lancet. Oncology|July 31, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialFred Saad, Joan Carles, Silke Gillessen, et al.
Cancers|May 14, 2022
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)Tobias Hölscher, Michael Baumann, Jörg Kotzerke, et al.
International Journal of Cancer|September 12, 2019
Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostateAngelika Borkowetz, Michael Froehner, Martina Rauner, et al.
European Urology|March 18, 2014
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, et al.
European Urology|May 24, 2011
The contemporary concept of significant versus insignificant prostate cancerGuillaume Ploussard, Jonathan I Epstein, Rodolfo Montironi, et al.
Pageof 10